Heron Therapeutics Stock News

Heron Therapeutics (NASDAQ:HRTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, “

COVID-19 has turned the world upside down, with the deadly virus inducing an unprecedented level of panic. Crushing economies across the globe, stocks seem to be taking hits left and right as the mark

COVID-19 has turned the world upside down, but the market’s most recent surge has Wall Street observers wondering if the situation is on the

Needham analyst Serge Belanger maintained a Buy rating on Heron Therapeutics (HRTX) today and set a price target of $44.00. The company's shares closed

Needham analyst Serge Belanger maintained a Buy rating on Heron Therapeutics ( HRTX – Research Report ) today and set a price target of $44.00 . The company’s shares closed last Tuesday at $14.85.

Nuveen Asset Management LLC raised its holdings in Heron Therapeutics Inc (NASDAQ:HRTX) by 83.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commiss

Alliancebernstein L.P. lifted its holdings in Heron Therapeutics Inc (NASDAQ:HRTX) by 2.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The

Geode Capital Management LLC grew its stake in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 22.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 1,132,260 shares of the biote

Bank of New York Mellon Corp lifted its position in Heron Therapeutics Inc (NASDAQ:HRTX) by 8.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission

This week we saw the Heron Therapeutics, Inc. (NASDAQ:HRTX) share price climb by 24%. But that is minimal compensation...

Shares of Heron Therapeutics Inc (NASDAQ:HRTX) were up 2.6% during trading on Wednesday . The stock traded as high as $13.59 and last traded at $13.90, approximately 32,745 shares traded hands during

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most importan

Heron Therapeutics and Intercept Pharmaceuticals are too cheap to ignore right now.

Bank of America Corp DE boosted its stake in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 29.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchan

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted